Ranbaxy exits Joint Venture with Nihon Pharmaceuticals
Leading pharmaceutical company Ranbaxy Laboratories has announced to sell its 50 per cent stake in its Japanese joint venture with Nihon Pharmaceutical Industry (NPI) without divulging the financial details of the deal. However, media reports claim that the buyer Nippon Chemiphar, founded in 1950, would pay $18 million for the 50 per cent stake.
Confirming the deal, Ranbaxy informed, "Following this transaction, NPI will become a wholly owned subsidiary of Nippon Chemiphar." The Gurgaon-based Indian company further informed that both firms would work independently for further enhancing their generic business in the Japan, the world's second largest pharmaceutical market after US.
Ranbaxy was earlier an independent group in India in the pharmaceutical segment but it is now a part of Japanese company Daiichi Sankyo which owns 64 per cent in the firm. The partnership break-up was widely speculated in the pharmaceutical sector as the Japanese firm already owns controlling stake in the firm.
Japan has been working on methodologies for providing more convenient environment through relaxed regulations in a bid to promote country as a favorite low-cost generic drugs hub in the world besides reducing the healthcare costs.






